Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carbinoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 0.83 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.83 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.83 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.83 |
| ▸ | LMNA | P02545 | 5/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.67 |
| ▸ | DRD1 | P21728 | 3/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.67 |
| ▸ | HTR1A | P08908 | 2/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.67 |
| ▸ | DRD3 | P35462 | 2/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbinoxamine SCHEMBL662375 | 0.94 | CHRM2 (0.93) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL9095143 | 0.93 | CHRM2 (0.91) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL4735208 | 0.92 | CHRM2 (0.76) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL29881788 | 0.91 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Rotoxamine SCHEMBL29485023 | 0.91 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Rotoxamine SCHEMBL141389 | 0.91 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL29414093 | 0.91 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL5070 | 0.91 | CHRM2 (1.00) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL8709373 | 0.90 | CHRM2 (0.97) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 | |
| Carbinoxamine SCHEMBL6626762 | 0.89 | CHRM2 (0.91) | CHRM2SLC6A2SLC6A4SLC6A3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742707-A4 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1742707-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | Hypnion, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005103041-A2 | TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS | HYPNION, INC. (US) | 2005-11-03 | — | — | WO | disclosed |